Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Goodman earnings: All eyes on data center progress

Our view after results.
stocks

Earnings winners: BHP, NAB & TLS lead the pack

The winners of this weeks earnings that saw strong investor backing
stocks

Walmart earnings: Growth in digital buoys margin amid consumer trade-down

We think Walmart stock is significantly overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,303.209.300.10%
CAC 408,515.49116.711.39%
DAX 4025,260.69217.120.87%
Dow JONES (US)49,588.98193.820.39%
FTSE 10010,686.8959.850.56%
HKSE26,413.35292.59-1.10%
NASDAQ22,875.73193.000.85%
Nikkei 22556,825.70642.13-1.12%
NZX 50 Index13,308.52135.68-1.01%
S&P 5006,905.3643.470.63%
S&P/ASX 2009,081.4017.000.19%
SSE Composite Index4,082.0751.95-1.26%

Market Movers